Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - After years of desire to be in the Japanese generics drugs business, Dr. Reddy's Laboratories Ltd. CEO G.V. Prasad reached that milestone in the signing of a memorandum of understanding with Fujifilm Corp. CEO Shigetaka Komori

You may also be interested in...

Fujifilm’s Sayonara To Dr. Reddy’s: Deal To Sell Generics In Japan Shelved

A high-profile joint venture between Fujifilm and Dr. Reddy’s to sell generic drugs in Japan has been terminated only two years after an initial MOU.

Lupin Adds Injectables Division In Japan with ¥3.1 Billion I'rom Pharmaceuticals Buyout

Lupin and I'rom also tie-up for Japanese clinical trial management as Indian firms see an improving generic drugs environment in Japan.

Top Japanese Pharmas Show Appetite For Emerging Market Expansion, Will Generics Follow?

TOKYO - Japanese pharma companies are trying to determine how to expand into new markets, ranging from the U.S. to China, and IMS Health data show a slow move away from dependence on the domestic market for Japan's leading companies

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts